Promise Advanced
quantification
Proteomics
innovates
in
protein
Tristan Rousselle, Co-founder and CEO, PX’Therapeutics; Chairman, acCInov (an industry
association affiliated with the LyonBiopole competitive cluster)
Jérôme Garin, Director, Large Scale Biology research unit (U1038); Director, IRTSV (CEAGrenoble’s Institute for Research in Life Sciences and Technology)
Promise Advanced Proteomics (http://www.promise-proteomics.com), a subsidiary of biotech
firm PX Therapeutics, offers protein analytics using PSAQ (Proteomic Standard Absolute
Quantification), a technology published and patented in 2007 by researchers at the CEA.
PSAQ uses proteins marked by stable isotopes as internal benchmarks for mass spectrometry,
a strategy that enables highly-accurate dosing of proteins within complex biological samples.
Applications include assessing potential biomarkers for pathologies, determining the
bioavailability of therapeutic proteins, checking water and food quality, and screening athletes
for performance-enhancing drugs.